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1. Introduction 
Liver is the largest organ in the human body and it functions like a metabolic factory. 
Disruption of its anatomical structure, which is often caused by excessive fibrosis of the 
extracellular matrix (ECM), when left unattended, can lead to cirrhosis of the liver and cause 
permanent and irreversible damage to its organization and function, with fatal 
consequences. Liver cirrhosis, which is generally the end result of chronic liver disease 
(CLD), can be caused due to many etiological reasons including (a) long term infections with 
hepatitis B and C viruses, (b) uncontrolled alcohol abuse, (c) excessive exposure to metabolic 
products of metals like iron and copper (d) autoimmune inflammation of the liver (e) 
nonalcoholic fatty liver disease (NAFLD) and (f) nonalcoholic steatohepatitis (NASH) 
(reviewed in [1]). Histo-pathologically, a hallmark of liver cirrhosis is the abnormal 
production and storage of collagen molecules in the ECM, formation of a scar tissue that 
replaces normal parenchyma and blockage of the portal flow of blood through the organ, 
thus affecting normal hepatocellular activity and ultimately total loss of liver functions [2, 
3]. Cirrhosis of the liver in early stages is largely asymptomatic, therefore remains 
undetected by physical examination and other available tests. Diagnosis of fibrosis at early 
stages and prevention of its progression to cirrhosis is a very important factor in the 
management of the disease. Among the different options available for treatment, this review 
would focus on cell based therapy for liver cirrhosis with a special attention on the 
challenges and procedures of using human fetal liver cells. Methods to improve the clinical 
application of cell and tissue imaging of liver in the management of cirrhosis would also be 
discussed, briefly. 
2. Treatment options for liver cirrhosis 
The established choices of treatment for cirrhosis are very limited and in most cases 
withdrawl of the underlying causative agent is used as the first line of treatment. Anti-viral 
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therapy and biochemical modulation of liver metabolism are some of the classical treatment 
strategies but more recently several cell therapy based options have been used albeit many 
are still experimental and limited to preclinical studies. Some of the approaches for 
treatment of cirrhosis are discussed below. 
2.1 Liver transplantation 
Liver transplant is considered to be one of the best curative treatment solutions available for 
advanced liver cirrhosis. However, the treatment procedure carries operative risk, is 
expensive, requires life long immunosuppression, and there is also a risk of graft rejection 
that requires a re-transplantation of the organ. One of the major limitations of liver 
transplantation is the availability of donor liver. There is a constant rise in number of 
patients on the waiting list for donor liver and an acute shortage on the availability, which is 
the leading cause for the increase in morbidity and mortality. This gap in the demand and 
supply of a donor liver tissue is partially filled by obtaining liver tissues from living donors 
and doing auxiliary liver transplantation. However, while opting for this procedure the 
possible risk to the donor and the benefits of the recipient must be considered. In this 
scenario, there is a clear need to look for alternative strategies for the therapy of end stage 
liver diseases that would be more effective and safe in reducing the tissue scarring of fibrotic 
livers and in redemption of normal liver function. 
2.2 Cell based therapy of liver diseases 
Cell based approaches for treatment of liver diseases offer novel but challenging alternatives 
to liver transplantation. Several types of stem and progenitor cells have been explored for 
their possible use in this field. Cell based therapies could be initiated by either (a) the 
activation or mobilization of autologous stem cells to the site of injury or (b) by the infusion 
of heterologous (or autologous) stem and progenitor cells from different sources. 
2.2.1 Activation of autologous regenerative cells 
The therapeutic role of autologous regeneration by resident cells in the liver or by mobilized 
cells from the bone marrow has a significant role to play in the auto regeneration of the 
normal tissue following liver injury. The failure of these mechanisms leads to the activation 
of degenerative cascades in the liver such as necrosis, cell death and abnormal accumulation 
of collagen. The autologous cell based therapies utilise the reactivation mechanisms where 
either the non responding resident cells in the liver are activated or fresh cells from the bone 
marrow are mobilised to the site of injury. 
2.2.1.1 Activation of resident regenerative cells in the liver by injectible growth factors 
In a cirrhotic liver the normal architecture is completely disrupted by abnormal 
accumulation of ECM components that block the vascular supply leading to the death of 
liver parenchyma which contributes to the decrease in liver function. The liver has a 
spontaneous regeneration potential to compensate for this loss of liver parenchyma by 
division of the existing hepatocytes and hepatic progenitor cells (HPC). However due to 
extensive scarring of tissue the regenerating cells are prevented from regaining their normal 
function. It is proposed that ECM remodelling can lead to resolution of this blockage and 
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reactivate the resident regenerative cells in the affected area. Earlier work on ECM 
remodelling by using matrix modifying factors such as hepatocyte growth factor (HGF) 
have shown prevention and/or regression of fibrosis in animal models of liver and 
pulmonary injury [4]. Administration of human rHGF or gene transfer of human HGF to 
rats with hepatic fibrosis/ cirrhosis caused by di-methyl-nitrosamine prevented the onset 
and progression of hepatic fibrosis/cirrhosis [5, 6]. Some of the studies have revealed that 
HGF mediates this process by directly antagonizing the pro-fibrotic actions of Transforming 
growth factor (TGF)-ǃ1 [7, 8]. In addition to these molecules, studies on basic fibroblast 
growth factor (b-FGF, FGF-2), in animal models, has shown their participation in tissue 
regeneration, angiogenesis and in wound healing processes [9]. A recent report has shown 
that activation of HPC might be linked up with ECM remodelling. Degradation of collagen I 
and subsequent laminin deposition seem to be important prerequisites for HPC activation 
and expansion [10]. Based upon these results it appears that a better understanding of the 
factors that govern HPC proliferation and the resultant ECM changes would provide clues 
to improve regeneration of liver cells in chronic liver disease.  
2.2.1.2 In situ mobilization of bone marrow cells to the liver 
Liver cirrhosis is associated with an intermittent mobilization of different types of bone 
marrow cells that are committed to differentiate to hepatocytes [11]. This process could be 
triggered either spontaneously upon liver injury or by administration of growth factors that 
could stimulate the migration of stem cells from the bone marrow into peripheral blood. 
Granulocyte-colony stimulating factor (G-CSF) is one such mobilizing agent that is receiving 
considerable attention recently in the field of liver therapy. Several studies have indicated 
that G-CSF may be effective in mobilizing bone marrow cells into the peripheral blood that 
contribute to liver repair [12, 13]. In rats G-CSF was shown to contribute to liver repair in a 
double mechanism by increasing the bone marrow derived liver repopulation, and also by 
activating the endogenous oval cells, that express G-CSF receptor (G-CSFR) [14].  
In a clinical trial, 8 patients affected by severe liver cirrhosis were administered G-CSF and 
the treatment was well tolerated in all the patients during a follow-up of 8 months, and 
mobilization of bone marrow stem cells co-expressing epithelial and stem markers was 
noted [15, 16] . Two independent studies on a group of 24 patients and 18 patients [17, 18] 
with severe liver cirrhosis resulted in a dose-dependent mobilization of good 
CD34+/CD133+ bone marrow stem cells and proved that the procedure was safe, but did 
not achieve any significant clinical improvement. Treatment with G-CSF was associated 
with the induction of HPC proliferation within 7 days of administration [19]. In a recent 
report G-CSF based mobilization of bone marrow cells was used successfully to treat 
patients even with acute on chronic-liver failure (ACLF), and a significant recovery in the 
clinical condition was noted [20]. Use of G-CSF could thus promote the in situ mobilization 
and regeneration of the liver tissue without excessive intervention and is slowly gaining its 
importance in the field of liver therapy.  
2.2.2 Infusion of therapeutic cells  
The discovery of stem cells has revolutionized the field of medicine offering potential 
options for the management of various chronic disorders. Different types of stem and 
progenitor cells from various sources are available with a broad potential for differentiation 
and application in tissue regeneration and newer sources are being explored. Several clinical 
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studies have been reported and reviewed where regenerative cells had been infused for the 
purpose of liver therapy and many other studies are currently in progress. 
Based on the donor tissue source and the differentiation potential of cells the results on the 
therapeutic efficacy of several cell types has been described below. 
2.2.2.1 Infusion of adult hepatocytes and Bio-artificial Livers (BALs) 
Adult hepatocytes are the fully mature functional cells of the liver that are highly 
specialized with the ability to divide and are an ideal source for transplantation. Though 
hepatocyte transplantation has been recognized as an attractive option for the management 
of metabolic liver disease some 35 years ago [21], lack of availability of livers for cell 
isolation, difficulty in expansion of hepatocytes in vitro and their sensitivity to freeze-thaw 
are major limitations for their routine use in cell therapy.  
Allogeneic primary hepatocytes isolated from cadaver livers and infused via the splenic 
artery or the portal vein showed an improvement in the clinical condition [22, 23, 24]. Many 
preclinical studies and clinical applications of this technique have been made to cure 
metabolic liver disorders and end-stage liver diseases [25]. In most instances, hepatocyte 
transplantation has been able to grant a clinical improvement for up to 12 months [26].  
Implantable hepatocyte-based devices and extra corporeal liver assist devices represent 
another alternative for the treatment of end-stage liver disease [27]. BAL devices are 
intended to support the failing functions of the organ, and include both a biological 
component (parenchymal cells) and an artificial scaffold serving as an interface with patient 
blood or plasma. Two main clinical trials have evaluated the efficacy of liver assist devices 
in patients with fulminant liver failure. Owing to the difficulty in supply of human 
hepatocytes, the devices included either purified pig hepatocytes (HepatAssist) or cell lines 
derived from liver cancer cells (ELAD) [28, 29]. Both trials failed to demonstrate a beneficial 
effect on survival. In the future, such devices are likely to re-emerge as a result of new 
technologies that allow growth and differentiation of large amounts of liver cells in vitro 
from stem/precursor cells. However, BALs will have to challenge cost-effectiveness in 
comparison with more convenient artificial devices. 
2.2.2.2 HPC’s and fetal liver cells (hepatoblasts)  
Isolation, expansion and differentiation of adult HPCs to functional hepatocytes has been 
described by several workers [30, 31, 32], however identification of a specific marker of 
HPCs still remains a challenge. Clinical studies on the repopulation of the human liver by 
HPCs are still awaited. 
Compared to the adult HPCs, fetal liver progenitor cells are highly proliferative, less 
immunogenic and more resistant to cryopreservation. The human fetal liver, between 10 
and 18 weeks of gestation, contains a large number of actively dividing hepatic stem and 
progenitor cells that are termed as hepatoblasts. These are bi-potent cells , that can give rise 
to both hepatocytes and bile duct cells; they co-express hepatocyte markers (such as 
albumin, ǂ-fetoprotein (AFP), ǂ-1 microglobulin, glycogen, glucose-6-phosphatase (G-6-P) and 
Hep-Par-1) and biliary markers, for example, gamma glutamyl transpeptidase (GGT), 
dipeptidyl peptidase IV (DPPIV), cytokeratin (CK)-19 and Das-1-monoclonal antibody-
reactive antigen, [33, 34]. These markers are expressed throughout the second trimester and 
thus offer opportunities to isolate and study large numbers of progenitor cells from abortuses.  
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2.2.2.3 Haematopoietic Stem Cells (HSCs) and Mesenchymal stem cells (MSCs) from the 
bone marrow 
HSCs are committed progenitor cells of the bone marrow and can be extensively expanded 
without loss of pluripotency. The bone marrow is an important source of autologous HSCs, 
and MSCs [35, 36]. Infusion of unsorted autologous bone marrow stem cells through the 
portal vein and hepatic artery in patients with cirrhosis, showed an improvement in Child-
Pugh score and albumin levels [16, 37]. A significant increase of liver function in cirrhotic 
and hepatocellular carcinoma patients was observed following autologous bone marrow 
stem cell transplantation prior to surgery [38]. However, use of unsorted bone marrow stem 
cells or MSCs must be treated with caution as these cells can also differentiate into 
myofibroblasts which are the scar forming cells of the liver [39]. Recent data also provides 
evidence to this in a rodent model where use of whole bone marrow as cell therapy led to 
the worsening of liver fibrosis [40]. Macrophages which are the cells of haematopoietic 
origin, are known to play a critical role in regulating liver fibrosis in murine models [41] and 
a single intra-portal administration of macrophages has recently been shown to reduce 
fibrosis in a murine model of liver injury and increase regeneration [40].  
MSCs and HSCs can also be isolated from other tissues such as peripheral blood, adipose 
tissue, umbilical cord blood (UCB) and placenta [42]. Adipose tissue derived MSCs have a 
good proliferative capacity in vitro and in vivo and can differentiate into hepatic cells [43-46]. 
The placenta and UCB are also important sources of young MSCs and HSCs that can be 
obtained without invasiveness or harm to donor and provide no ethical barriers for basic 
and clinical applications [47, 48]. Recently UCB cells were used on a diverse group of end 
stage cirrhotic patients with an improvement in the life span in these patients [49] raising a 
hope on the use of these cells for liver cell therapy.  
MSCs and HSCs from all sources display a high degree of plasticity giving rise to a wide 
range of phenotypes, including hepatocyte-like cells. The low immunogenic property of 
these cells have shown promising results with the use of these cells in in vitro studies and 
clinical trials [50-55]. 
2.2.2.4 Embryonic and Induced pluripotent stem cells (iPSCs) 
Embryonic stem cells (ESCs) derived from the inner cell mass of 5-6 day old embryos have 
the advantage of being able to proliferate in an unlimited fashion and might constitute an 
easily available source to obtain a large number of transplantable cells for regenerative 
treatments. By manipulating the factors responsible for maintaining the undifferentiated 
state of these cells and by exposure to appropriate growth factors in vitro, ESCs can be 
directed towards the hepatic lineage. ESC-derived hepatocyte-like cells were able to colonize 
the injured liver and function as mature hepatocytes without teratoma formation in several 
animal models of liver disease [26, 56, 57]. Due to the propensity of these cells to form both 
malignant and non-malignant tumors, caution has to be still exerted for their use in 
transplantation. The ethical issues regarding the use of human embryonic stem cells will 
also have implications for their clinical use. 
Induced pluripotent stem cells offer a solution to this ethical concern and the risk of rejection 
related to embryonic stem cells. iPSCs are generated in vitro by genetic reprogramming of 
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adult somatic cells with certain factors, to form pluripotent stem cells with embryonic-like 
differentiation potential [58]. Hepatocytes derived from iPS cells have a reasonable synthetic 
and metabolic capacity [59], and seem to be similar to cells derived from ES cells [60-62]. 
However, the same concerns of tumor formation or reversion to more primitive state with 
uncontrolled expansion within the recipient still remain. In spite of these limitations iPS-
derived hepatocytes are a very promising population for cell therapies in hepatology.  
3. Management of end stage liver disease with fetal liver cells 
Hepatic progenitors derived from the livers of electively aborted fetuses of 5 to 20 weeks 
gestation are generally designated as “multipotent.” Fetal cells seem to have an edge over 
embryonic stem cells in that, being less versatile, they may not form teratomas and exhibit 
an important property of being less immunogenic by the little to no expression of the Class 
II HLA marker on their surface, which otherwise can trigger a rejection reaction [63]. Thus, 
tissue matching that is a prime requirement in blood transfusions, organ transplants, and 
allogenic adult stem cell transplantation is not necessary when transplanting these cells.  
3.1 Hepatic progenitors in developing liver  
The developing human (and also murine) liver during early to mid gestation has been 
shown to comprise stem and progenitor cells that can give rise to the different adult cell 
types. The developmental plasticity of fetal liver parenchymal cells, at this stage of organ 
development, makes them a very good source for cell therapy. During the first trimester of 
fetal development, the liver serves as the site for hematopoiesis and later during the mid-
gestation the hematopoietic cells migrate to the bone marrow and the liver starts functioning 
primarily as a hepatic organ (Figure 1). In the first trimester, human fetal liver is the site of 
synthesis of progenitor and stem cells of many lineages but during the second trimester, 
markers for hepatoblasts continue to be expressed but the expression of markers for other 
lineages is reduced [63, 64]. This offers an opportunity to isolate and study large numbers of 
hepatic progenitor cells without haematopoietic potential during the second trimester of 
gestation. It is interesting that hepatic progenitor cells isolated from human fetal liver 
proliferate for several months and retained their normal karyotypes, thereby indicating a 
strong telomerase activity in them [65].  
3.1.1 Cell surface and intracellular markers for progenitor cells 
Many different markers have been used for the identification of progenitor cells. Bi-potential 
progenitors have been isolated from fetal mouse liver in a number of studies. Petersen et al 
have established that a Thy-1+ve cell population within the rat fetal liver also expressed CK-
18, a hepatocyte marker [66]. Hepatic progenitor cells have also been reported to express c-
kit, a hepatic stem cell marker, along with CD34 and Thy-1 [67]. In a study from our lab, 
CD34 cells from human fetal liver were found to be expressing hepatic and biliary markers 
as well [64]. In another study with human fetal liver cells, Thy-1+ (a haematopoietic marker) 
cell populations were isolated that were found to be positive for progenitor (CD34, c-kit, 
CK14, M2PK, OV6), biliary (CK19) and hepatic (HepPar1) markers, revealing their 
progenitor as well as hepatic and biliary nature [68]. Expression of these specific markers by 
each cell type is used for the isolation of progenitor cells. 
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Fig. 1. Transition of cells during liver development 
Obtaining good quality and quantity of fetal progenitor cells is very important to ensure 
repopulation of the liver upon transfusion of these cells. Care must be ensured at every step 
of tissue collection, isolation of progenitor cells and transfusion of the cells in order to study 
the efficiency of these cells in treating liver diseases. Some of the important challenges and 
procedures in these approaches are discussed below. 
3.2 Ethical and logistic challenges in obtaining human fetal tissues 
The use of human fetal tissues for preclinical or clinical work is always controversial due to 
religious and ethical issues. The main challenge is the procurement of fetal tissue, therefore 
the first important step is to identify a maternity/obstetric hospital/department willing to 
donate aborted fetuses of known gestation period and acceptable medical history for 
research in good clinical grade condition. The following measures need to be ensured for 
collection and use of fetal material: 
a. Ethical clearance: Clearances to work with human fetal material must be obtained from 
the hospital and the research institute’s ethical committee where the fetal cells would be 
isolated and processed, prior to beginning of the work.  
b. Informed consent: The mother must be properly informed of the procedure and the 
written consent must be obtained for the donation prior to the abortion. The process of 
abortion and donation must be maintained as separate procedures to ensure that the 
fetus is donated voluntarily and no financial gain is involved in the process.  
c. Screening procedures: All donors of the fetus must be serologically screened for 
syphilis, toxoplasmosis, rubella, hepatitis B and C, human immunodeficiency virus 1, 
cytomegalovirus, parvovirus, and herpes simplex types 1 and 2. 
d. Gestational age: The gestational age of the fetus is very important and should not cross 
the second trimester of gestation. The sample should preferably be chosen from an 
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elective abortion in order to ensure that the tissue is intact and must be collected 
immediately after the procedure and stored in cold conditions. 
e. Transportation of fetal material: Once the tissue is collected it must be stored in a clean 
sterile container with controlled temperature to ensure that the cells are not affected 
with the temperature changes during the transport. The tissue must be transported to 
the processing lab as quickly as possible maintaining proper sterile procedures. The 
cells must be isolated in clean sterile conditions within a maximum of 4 hours of the 
abortion. If the cells are to be used immediately for transfusion then the processed cells 
must be enumerated and transported to the hospital in sterile vials ensuring proper 
temperature conditions. 
f. Storage of cells: The cells that would not be used immediately should be enumerated 
and stored with a safe cryo preservative such as DMSO in liquid nitrogen until further 
use. The viability of the cells during the freeze thaw must be checked before the frozen 
cells are used for transfusion.  
3.3 Preparation of cells from human fetal tissue for therapeutic use: 
Once a fetus of the appropriate gestation age is obtained in good medical condition, cell 
isolation should be done within 4 hours in order to obtain good viability of cells. Two main 
steps are involved in this process: (a) Isolation of total viable cells from the liver, and (b) 
enrichment of progenitor cells suitable for transfusion. 
3.3.1 Isolation of viable liver cells 
The cells in the liver tissue are connected by intercellular connections and tight junctions 
embedded in an ECM that needs to be disrupted or dissolved for single cell isolation. Three 
different approaches for isolating viable liver cells with some modifications are principally 
used: 
1. Mechanical dispersion using partial homogenization and forcing the liver tissue 
through steel meshes [69]. 
2. The second method of hepatocyte isolation includes removal of calcium and potassium 
from liver by perfusion and reverse perfusion with calcium binding agent like citrate, 
Ethylene diamine tetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), tetra 
phenyl borate (TBP), pyrophosphate, versine and ATP in calcium free Locke’s solution 
as a sole means of separating intracellular spaces [70, 71]. 
3. The third method involves the dissolution of intracellular junctions by using proteolytic 
and matrix dissolving enzymes like trypsin, papain, lysozyme, neuraminidase and 
pepsin [72, 73]. 
4. Recently a new protocol for efficient and quick isolation of fetal liver cells from 18-24 
weeks of gestation was developed. The protocol involved a 5 step portal vein in situ 
liver perfusion technique using both EGTA and limited exposure to collagenase that 
resulted in a greater and efficient cell yield [74].  
The human fetal liver cells thus isolated can be used as such for treatment of liver failure in 
model animals and even in experimental clinical trials or can be enriched further for specific 
progenitor cells. 
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3.3.2 Enrichment of progenitor cells  
The total liver cells that are isolated are a mixture of different population of cells from which 
the progenitor cells are isolated based on their specific properties by using any of the 
following enrichment methods. However the method of using the surface markers for 
enrichment is more efficient in specifically selecting progenitor cells.  
a. Enrichment based on size and density: Cells of a particular lineage or function have a 
specific size and mass and this property has been used to separate out desired 
population of cells from a mixture of cells. Several investigators have used physical 
methods like density gradient centrifugation and counter flow centrifugation elutriation 
methods for the enrichment of the hepatic progenitors. Yaswen et al., demonstrated the 
enrichment of hepatic oval cells (hepatic progenitor) using Centrifugal elutriation 
(Beckman Instruments, Palo Alto, Calif.) of the cell suspension [75]. Enriched fraction 
was characterized histochemically for gamma-glutamyl transpeptidase, peroxidase, 
alkaline phosphatase, glucose-6-phosphatase activities, albumin and alpha-fetoprotein 
by immunocytochemical methods [75]. 
b. Enrichment based on surface markers: The enrichment of cells can be achieved by 
using surface markers specifically expressed by the progenitor cells. The process uses 
antibody specific for the surface marker and separation is achieved by either 
magnetically tagged (MACS) or fluorescently tagged (FACS) antibodies. In our 
experience, though FACS is more sensitive for enriching a specific cell type based on 
the marker expression, the cell yield is not very efficient. Hence enrichment using 
MACS is more efficient in giving a good yield of the desired population of cells. 
Studies with human livers have shown that Epithelial cell adhesion molecule (EpCAM) 
is expressed by hepatic stem cells, hepatoblasts and committed progenitors but not 
expressed in mature hepatocytes [76, 77]. Thus, sorting for EpCAM results in only 
progenitor cells but in distinct ratios of hepatic stem cells to hepatoblasts depending 
upon whether the tissue is fetal, neonatal, or adult. In our recent study we have also 
enriched the hepatic progenitors using EpCAM and further characterized using liver 
specific and stem cell markers such as CD29, CD90, CD49f, CD34 and we found that 
EpCAM +ve cells expressed intermediate levels HLA class I but no HLA class II. Our 
study demonstrated the usefulness of EpCAM as a novel surface marker for enrichment 
of hepatic progenitors [63]. Earlier we have also used CD34+/CD45- as one the marker 
for the hepatic progenitors [64]. 
c. Separation based on Functional markers: Certain types of cells express functional 
receptors on their surface, which transport molecules out of the cells. One such 
transport protein is the ATP-binding cassette sub-family G member 2 (ABCG2) 
transporter protein that specifically excludes the Hoechst dye. Separation of progenitor 
cells can be achieved using this functional marker where the cells specifically exclude 
the Hoechst dye [78, 79]. 
3.3.3 Characterization of liver progenitors 
The enriched progenitor cells must be further characterized for the expression of hepatic 
and biliary markers by using methods such as flow cytometry, immune histochemistry and 
RT-PCR. Hepatic progenitor cells express many markers that are similar to hepatocytes or 
bile duct cells, and also share some of the haematopoietic markers, AFP, certain keratin 
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markers [e.g., cytokeratin 19 (CK 19)], and Gamma glutamyl transpeptidase (GGT) [80]. In 
our study, fetal progenitor cells enriched with EpCAM marker were further characterized 
for the expression of liver epithelial markers (CK18), biliary specific marker (CK19) and 
hepatic markers (albumin, AFP) by RT-PCR. FACS indicated that the cells were positive for 
CD29, CD49f, CD90, CD34, albumin and AFP and negative for HLA class II and CD45. 
Immunocytochemical staining confirmed the expression of CK18 and albumin [63]. In a 
study by Lie et al., epithelial progenitor cells from human fetal livers were isolated by cell 
culture and characterized for their expression of liver epithelial markers (cytokeratin [CK8 
and CK18) and biliary-specific markers (CK7 and CK19) by real time PCR. FACS analysis 
was used to confirm the expression of hepatic markers such as CD117, CD147, CD90, CD44, 
and absence of hematopoietic markers such as CD34 and CD45. Hepatic differentiation 
potential of these cells was also confirmed both in vitro and in vivo [81].  
3.4 Treatment of patients with human fetal liver derived cells 
Treatment of patients with fetal cells is slowly gaining its importance in the field of cell 
therapy with encouraging outcomes and improvements in the clinical conditions. However, 
the success of such procedures is largely dependent on several factors such as age of the 
patient, type and stage of the disease progression and the route and site of cell injection 
chosen. Each of these factors are variable for every patient and must be chosen carefully 
before administering the cells. Some of these factors and the success of the treatment 
procedures are discussed below: 
3.4.1 Categories of patients selected for treatment with fetal cells 
Several end stage liver diseases have been treated by liver cell based therapy with different 
degrees of success; a summary of these findings so far, is given below 
1. Acute liver failure is characterized by loss of liver cells leading to encephalopathy. Initial 
study by Habibullah et al., showed that fetal hepatocyte transplantation may be beneficial 
in patients with ALF in grade III or IV encephalopathy [82]. Also, the transplanted 
hepatocytes may proliferate under the influence of hepatotropic factors thereby increasing 
their total metabolic and detoxifying capacity. In another study five patients comatose 
with acute liver failure received transplantation of 1.3×109 to 3.9×1010 cryopreserved 
hepatocytes through intrasplenic and intraportal infusion and three patients showed 
improved result in encephalopathy score and some liver functions [83]. At our centre we 
have also performed intra-peritoneal transplantation of hepatocytes in a 26 yr old acute 
fatty liver of a pregnant patient who recovered within two days of transplantation [84].  
2. Metabolic Liver Disease Hepatocyte transplantation into the liver corrected deficiency. 
In a landmark trial a child with Crigler-Najjar type I, suffering from dangerous hyper 
bilirubinaemia, was given 7.5x109 allogenic donor hepatocytes by infusion via portal 
vein catheter [85]. This procedure resulted in reduction of serum bilirubin levels. 
Recently, in our study on Crigler-Najjar type I syndrome the patient treated with fetal 
liver derived hepatic progenitors showed a decrease in the total bilirubin and increase 
in the conjugated bilirubin [86]. Hepatocyte transplantation in a 4 year old patient with 
infantile Refsum disease led to partial clearance of abnormal bile acids with pipecholic 
acid being reduced to 60 per cent of pre-transplantation levels. The child was able to 
stand and walk 6 months after hepatocyte transplantation [87]. 
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3. Cirrhosis of liver This category of liver disease is more appropriate for cell therapy and 
efficacy of various sources of cells has been demonstrated. Late stage progressive 
hepatic fibrosis characterized by distortion of hepatic architecture, necrosis of 
hepatocyte and formation of regenerative nodules leads to cirrhosis. Cell based therapy 
is emerging as an efficient method of treatment in the management of decompensated 
liver cirrhosis [88]. Treatment of liver cirrhosis using different sources of cells has been 
used by several investigators. Procedure and results of these studies has been discussed 
in section 3.4.3. 
3.4.2 Infusion of cells into patients 
The survival, proliferation and engraftment of transplanted/infused therapeutic fetal cells 
are critically dependent on the route of cell delivery and the physiological condition of site 
of transplantation. The most appropriate site of transplantation is directly into the liver, 
however because of some limitations of the clinical conditions, several ectopic sites such as 
the peritoneum, spleen also have been attempted. 
3.4.2.1 Sites and routes for cell infusion/transplantation 
Several routes to deliver the cells into the liver have been used with varying degrees of 
success. Cells for transplantation have usually been delivered to liver through hepatic artery 
[89] or through portal vein [90]. (The different routes for cell infusion are schematically 
depicted in figure 2). 
a. Hepatic artery: Hepatic artery can be accessed through trans femoral, trans radial, trans 
brachial. In our experience hepatic artery route is more convenient compared to hepatic 
portal vein [91]. Though highly efficient, direct deliveries into liver might pose the risk 
of occlusion and in certain cases fibrosis, due to portal hypertension and embolism of 
cells. 
b. Portal Vein: Portal vein can be accessed by percutaneous trans hepatic approach or 
trans jugular approach. The hepatic portal vein drains blood from the gastrointestinal 
tract and spleen into the liver. It is more often used compared to the hepatic artery 
because multiple vascular accesses are more practical through the vein. However the 
limitations of being a major procedure and the risk of bleeding must be considered for 
using the trans-jugular approach for delivery of cells through portal vein 
Accessing portal vein through percutaneous trans-hepatic approach is difficult in the 
presence of ascites which is a common clinical problem in the end stage of liver disease.  
c. Splenic Approach: The most appropriate ectopic site is the splenic pulp within the 
spleen. Spleen has a rich blood supply which is accessible to hepatic portal circulation, 
leading to the translocation of the transplanted cells to the hepatic sinusoids. Direct 
intrasplenic injection was suggested as a better method to transplant hepatocytes 
compared to the splenic artery infusion, since the latter led to vascular occlusion with 
hepatocytes, gastric erosion, and large areas of splenic necrosis [92]. In a recent study 
fetal cells were transplanted in a patient with end stage cirrhosis via the intrasplenic 
infusion through the splenic artery leading to improvement in the clinical condition 
[74]. Studies have demonstrated that after injection into the splenic pulp, most 
hepatocytes immediately translocate to splenic veins and then to hepatic sinusoids, 
although hepatocytes trapped in splenic sinusoids may engraft in the spleen itself [93]. 
www.intechopen.com
 
Liver Regeneration 228 
 
Fig. 2. Different routes for cell infusion  
3.4.3 Efficacy and safety evaluation 
The safety and efficacy of the fetal and other cell based treatment of end stage liver disease 
need to be constantly evaluated and revised as per the new protocols as they become 
available. Comparison of the different cell types and the routes of cell delivery has provided 
different alternatives for treatment of this disease. For example, our group demonstrated the 
efficacy of fetal hepatic progenitor cells, delivered through the hepatic artery in 25 cases of 
de-compensated liver cirrhosis, resulting in significant clinical improvement in more than 80 
% cases. The hepatic angiogram showed no sign of thrombosis/narrowing/ischemia in the 
hepatic artery when analyzed after successive time intervals (Figure 3) [91].  
Further data on immune status of allogenic transplantation of human fetal derived 
progenitors showed no significant changes in the immune status (T cells, NK cells, and 
Cytokines). The availability of long-term (> 3 years) follow-up data further confirms the 
safety and efficacy of this therapy. None of the patients recruited in this study developed 
any procedure/therapy related complications as demonstrated by liver angiograms that 
were taken pre- and post-transplantation of cells. In another study from our lab [86], 
infusion of bone marrow derived CD34+ cells in 5 cases by the same route also showed 
good outcomes in a 6 month follow up.  
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Fig. 3. Comparison of First and second Hepatic arteriogram following administration of 
Hepatic Progenitor cells to patient with Liver Cirrhosis (Khan et al., 2010) 
Several studies have demonstrated the presence of cells of bone marrow origin in the human 
liver. This was elegantly demonstrated with bone marrow transplantation in female patients 
who received bone marrow from male donors and were found to be carrying Y-
chromosome- and CK8- positive hepatocytes, thus, suggesting that extrahepatic stem cells 
can engraft in the liver [94]. An improvement of liver function and hepatocyte production 
was seen in nine patients with liver cirrhosis after the infusion of bone marrow cells through 
peripheral vein [37]. In another study, 2 patients with alcoholic- induced liver cirrhosis were 
treated with autologous mobilised HSCs [95]. In a study on 10 patients with chronic end-stage 
liver disease transplantation of committed progenitor cells and no bone marrow cells via the 
hepatic artery, showed an improvement in liver function [96]. A significant clinical 
improvement in the liver function, and Child-Pugh Score was seen in ten patients with 
advanced liver cirrhosis due to hepatitis B infection following autologous bone marrow 
infusion [97]. Pai et al., reported a study where autologous expanded mobilised adult bone 
marrow CD34+ cells were administered via the hepatic artery in 9 patients with alcoholic 
liver cirrhosis. Significant decrease in serum bilirubin, ALT, and AST levels were observed, 
whilst the Child-Pugh Scores and radiological ascites improved in 7 and 5 patients, 
respectively [98]. 
3.4.4 Tracking and monitoring the fate of transplanted cells  
One of the major problems facing the delivery and monitoring of cell transplants is their 
noninvasive in vivo visualization. Tracking of transplanted cells is a very challenging area of 
cell based therapy. Monitoring transplanted cells becomes imperative in order to understand 
the route of migration of cells upon injection. It is important that the cells do not enter the 
pulmonary capillaries as this could lead to complications. In deciding choice of the tracking 
agent the primary points to be considered are safety of the tracking agent upon administration 
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and the duration that the tracking agent can provide signals to be able to track the cells. The 
tracking agent must not cause any effects to the viability or multiplication of the transplanted 
cells. Though multiple studies have used various biomarkers in pre-clinical studies, their 
feasibility in human clinical studies warrants further validation. 
In one of our clinical studies, tracking of the cells labeled with Tc-HM-PAO was done after 
cells were infused through hepatic artery (Figure 4). Hepatic scintiography showed that 
transplanted human fetal hepatic progenitor cells homed in the total lobes of liver with a 
high rate of engraftment, thereby again reiterating the effectiveness of hepatic artery in the 
cell delivery. No other clinical complications were observed during and after 6 months of 
follow-up [91]. 
 
Fig. 4. Tc 99m HMPAO Progenitor cell labeling (Khan et al., 2010) 
4. Basic studies in animal models to monitor the progression of the disease 
and treatment 
Over the last decade several advancements have been made in the area of liver disease 
management. Further research is required to improvise the tissue imaging methods and 
new technologies are needed to monitor the fate of the cells that are injected. Animal models 
serve as efficient systems to study these methodologies. 
4.1 Non-invasive monitoring of the transplanted cells 
Monitoring the fate of transplanted cells over time is important to understand the route of 
cells migration and also to evaluate the efficacy of the transplanted cells. Several different 
methods based on magnetic, fluorescence or radio imaging are currently being evaluated for 
their efficiency in detecting transplanted cells. Though some of the methods are currently 
being used in clinical settings majority are still in the preclinical stages.  
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4.1.1 Radionuclide imaging  
Radionuclide imaging is a very sensitive method that utilizes radio labeled markers for 
detection of cells. Single photon emission computed tomography (SPECT) and positron 
emission tomography (PET), allow the imaging of radio labeled markers and their 
interaction with biochemical processes in living subjects. SPECT provides the advantages of 
cell quantification, and lower background signals, but also has disadvantage of a lower 
spatial resolution compared with MRI and optical imaging [99]. 
PET is more sensitive than SPECT and permits more accurate quantification of cell numbers. 
Long term expression of reporter genes such as herpes simplex type 1 thymidine kinase 
(HSV1-tk) for PET imaging is more beneficial than direct and indirect labeling as the cells 
divide and increase the signal and is also indicative of viability of the cells [100, 101]. The 
use of reporter gene imaging is currently limited only to animal model studies and needs 
further validation for its use in clinical settings. 
Using radiolabeling the organ bio distribution of human adult hepatocytes and fetal liver 
cells upon transplantation, was studied in NOD/SCID mice. The cells were labelled with 
indium-111 (111In)-oxine and technetium-99m (99mTc)-Ultratag or 99mTc-Ceretec and 
injected via the intrasplenic or intraportal routes. The adult hepatocytes and fetal liver 
stem/progenitor cells incorporated 111In but not 99mTc labels and the tracking of the cells 
confirmed that the cells were retained in the liver and spleen without translocating into 
pulmonary or systemic circulations [93].  
4.1.2 Magnetic Resonance Imaging (MRI)  
MRI provides a high spatial and temporal resolution in monitoring the distribution, 
migration, survival and differentiation of the transplanted cells in animals over weeks, in 
vivo. Cells are labeled in advance with contrast agents such as gadolinium-
diethylenetriamine penta-acetic acid (Gd-DTPA) for short-term monitoring for upto a week, 
or superparamagnetic iron oxide (SPIO) for long-term monitoring (reviewed in [102]). Since 
these contrast agents are exogenous and are often degraded, efforts to develop suitable 
reporter genes such as the transferrin receptor (TfR) gene that is highly expressed on the 
target cell membrane have been done for years, however the field is still in its early stage 
[103, 104]. The major limitation with MRI is the inability to distinguish viable from 
nonviable cells or proliferating from non-proliferating cell populations. Further it also, 
cannot distinguish iron-labeled cells from free iron released upon cell death, therefore, iron 
particle labeling should better be looked as a marker for high-resolution detection of cell 
location rather than monitoring cell viability in MRI stem cell tracking [105]. 
4.1.3 Bioluminescence, fluorescence and infra red imaging  
Bioluminescence and fluorescence imaging are efficient, noninvasive methods that provide 
rapid assessments of transgene expression in preclinical models [106]. Bioluminescence 
imaging is based on transgenic expression of certain bioluminescent genes such as the 
luciferase gene in transplanted cells and the in vivo detection is done by injecting the non-
toxic bioluminescent substrate solution and the photons that are generated are captured to 
provide the images [107-109]. However, bioluminescence is limited by a lower spatial 
resolution and the inability to produce 3-dimensional and tomographic images [105]. 
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Fluorescent imaging is based on the fluorescence property of a widely used protein such a 
green fluorescent protein (GFP) that is also introduced into the transplanted cells for stable 
expression [110]. Due to the low tissue penetrance and non-specific background generated 
by the autofluorescence of the surrounding tissue GFP reporter cannot be used to reliably 
track in vivo characteristics of transplanted stem cells [109-112].  
Imaging in the near-infrared (NIR) wavelength (700–900 nm) spectrum can maximize tissue 
penetrance in addition to minimizing the autofluorescence from non target tissue. Our lab is 
currently working on tracking transplanted cells using the fluorescent dye Di-D. EpCAM 
+ve human fetal liver cells were labeled with Di-D and injected in the liver of nude mice to 
monitor their survival and engraftment of the liver. Using Di-D the labeled cells were 
imaged with KODAK Fx PRO animal imaging system at various time points indicating the 
persistence of fluorescencent labeled EpCAM+ve cells upto 110 days post transplantation 
(Figure 5). The fluorescence images of animal were overlaid with the X-ray images of the 
animal. Further studies on the safety and efficacy of the dye needs to be confirmed before 
clinical trials could be attempted.  
 
Fig. 5. In vivo images of nude mice after intra hepatic transplantation with DiD labeled 
EpCAM +ve cells at different time points (Unpublished data) 
4.2 Need for more non- invasive tissue imaging methods to monitor disease 
progression 
Non-invasive tissue imaging methods to detect fibrosis play an important role in the 
management of liver disease. Methods to monitor the disease progression are as important 
as the treatment procedures, as timely detection of fibrosis could help in prevention of the 
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further progression and restore the liver functions with minimal intervention or cell 
therapy. Imaging methods offer an invaluable diagnostic tool in detection and monitoring 
the disease progression.  
The conventional methods of imaging such as the ultrasonography and computed 
tomography are routinely used in the evaluation of fibrosis but with limited success in 
predicting the stage of the disease. The more recent methodologies based on elastography 
such as the fibroscan (ultrasound elastography) and Magnetic Resonace elastography (based 
on magnetic resonance) measure the stiffness of the tissue and correlate to the extent of 
disease progression and are more sensitive to detect fibrosis. However, the sensitivity of 
these methods are limited to detect fibrosis only in later stage of disease progression and 
new sensitive methods need to be developed that can predict the early fibrotic changes of 
the liver. Since fibrosis is characterized by extensive and unorganized accumulation of ECM 
with the principal component being collagen, our lab has initiated work on this front by 
targeting collagen to detect fibrosis. We propose to achieve this by using probes that are 
specific to collagen and combine these to a fluorescent or magnetic reporter molecule that 
would be detected by imaging methods. The amount of collagen detected would be 
correlated to the stage of fibrosis. Studies are currently being carried on rat and mouse 
models and would need extensive confirmation before these can be extended to human 
studies.  
5. Conclusions 
Cell based treatment is a promising area which is slowly gaining importance as a 
therapeutic approach for liver diseases. Preclinical and clinical trials with different types of 
adult cells have provided evidence for their usefulness in treating cirrhotic liver disease 
though with certain limitations. Recently, human fetal progenitor cells with their low 
immunogenicity and a good proliferative capacity are emerging as safe and potential 
sources for treating liver diseases. However, the efficiency of these cells in treating various 
types of liver diseases is yet to be established. Long term monitoring of the fate of the 
transfused cells also remains a challenging area that needs to be addressed before these cells 
can be used as routine treatment options for liver diseases. Improvised methods of cell 
isolation and infusion in patients and the development of faster and efficient non-invasive 
methodologies for detecting fibrosis at early stages would be an important step towards the 
management of liver diseases.  
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